Aybatli, AysunKaplan, Petek BalkanliAlicik, MehmetSayin, Niyazi CenkYuce, Mehmet Ali2024-06-122024-06-1220112146-31232146-3131https://doi.org/10.5174/tutfd.2009.02161.1https://hdl.handle.net/20.500.14551/206736th Congress of Gynecology and Obstetrics -- MAY 14-19, 2008 -- Antalya, TURKEYObjective: To evaluate the efficacy of single dose intramuscular methotrexate in the treatment of ectopic pregnancy. Material and Methods: 32 patients who matched the inclusion criteria were enrolled. Success of treatment was defined as a resolution of ectopic pregnancy without performing surgical intervention. The cases in whom the treatment was successful and those that were not were compared for beta-hCG values and clinical features. Results: beta-hCG at diagnosis averaged 1293.9 mlU/ml. Of the 32 patients who received methotrexate, 26 were successfully treated. 23 patients (71.8%) received a single dose of methotrexate, 3 patients (9.3%) received an additional dose of methotrexate, 6 patients (18.7%) who had failed methotrexate required surgery for cure. The success rate of single-dose methotrexate was 79.3%. Conclusion: Our study shows that single dose systemic methotrexate treatment can be used as an option in unruptured pregnancies.en10.5174/tutfd.2009.02161.1info:eu-repo/semantics/openAccessEctopic PregnancyMethotrexateBeta-HcgSingle DoseMedical-ManagementFailureConference Object2811013N/AWOS:0002930598000032-s2.0-79959670752Q3